title: The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
abstract: Canine osteosarcoma, an aggressive cancer with early distant metastasis, shows still despite good chemotherapy protocols poor long term survival. The aim of our study was to determine whether sorafenib, a novel multikinase inhibitor, has any effect on D-17 canine osteosarcoma cells. A cell proliferation kit was used for detecting surviving cells after treatment for 72 h with sorafenib or carboplatin or their combination. A significant decrease of neoplastic cells was observed after incubation with 0.5-16 microM sorafenib or with 80-640 microM carboplatin. Using immunocytochemistry for activated caspase 3 to evaluate apoptosis, we found significantly more positive cells in the sorafenib treated groups. Paradoxically, expression of the nuclear proliferation marker Ki-67 was also significantly higher in sorafenib treated cells. The drug sorafenib showed potent antitumour activity against D-17 canine osteosarcoma cells in vitro, suggesting a potential as a therapeutic tool in the treatment of bone cancer in dogs.
authors: Department for Companion Animals and Horses, University of Veterinary Medicine, Vienna, Austria. birgitt.wolfesberger@vu-wien.ac.at
authors: B
authors: B
authors: Wolfesberger
authors: Z
authors: Z
authors: Tonar
authors: W
authors: W
authors: Gerner
authors: M
authors: M
authors: Skalicky
authors: G
authors: G
authors: Heiduschka
authors: M
authors: M
authors: Egerbacher
authors: J G
authors: JG
authors: Thalhammer
authors: I
authors: I
authors: Walter
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D001557:Benzenesulfonates / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000662:veterinary*; D053148:Caspase 3 / Q000378:metabolism; D002452:Cell Count; D045744:Cell Line, Tumor; D004283:Dog Diseases / Q000188:drug therapy* / Q000201:enzymology; D004285:Dogs; D005434:Flow Cytometry; D019394:Ki-67 Antigen / Q000378:metabolism; D046529:Microscopy, Electron, Transmission; D009536:Niacinamide / Q000031:analogs & derivatives; D012516:Osteosarcoma / Q000188:drug therapy / Q000201:enzymology / Q000662:veterinary*; D010671:Phenylurea Compounds; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D019394:Ki-67 Antigen; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases; D053148:Caspase 3